Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Lenalidomide Enhances the Biological Activity of Galiximab Against Non-Hogkin’s Lymphoma In Vitro and In Vivo .

Nishitha Reddy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Joy Knight, MS, Czuczman S. Myron, MD, (Intr. by Myron S. Czuczman)

Blood (2007) 110 (11): 2353.

https://doi.org/10.1182/blood.V110.11.2353.2353

Published: 2007

Journal Articles

GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens.

Elizabeth A. Gruber, BS, Myron S. Czuczman, MD, Scott H. Olejniczak, PhD, Joy Knight, MS, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2007) 110 (11): 1389.

https://doi.org/10.1182/blood.V110.11.1389.1389

Published: 2007

Journal Articles

Methylseleninic Acid (MSA) Decreases DNA Synthesis, Induces Cell Death, and Sensitizes Both Rituximab Sensitive and Rituximab-Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Cisplatin and Gemcitabine.

Francisco J. Hernandez-Ilizaliturri, MD, Minhas Ali, MD, Joy Knight, MS, Youcef M. Rustum, PhD, Myron S. Czuczman, MD

Blood (2007) 110 (11): 4517.

https://doi.org/10.1182/blood.V110.11.4517.4517

Published: 2007

Journal Articles

Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF) Enhances Mapatumumab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) Against Non-Hodgkin’s Lymphoma (NHL) Cell Lines Independent of NADPH Oxidase-Derived Reactive Oxidant Intermediates (ROIs).

Lyudmyla Derby, MD, Francisco J. Hernandez-Ilizaliturri, MD, Brahm H. Segal, MD, Joy Knight, MS, Jennifer Bushey, MS, Myron S. Czuczman, MD

Blood (2007) 110 (11): 4519.

https://doi.org/10.1182/blood.V110.11.4519.4519

Published: 2007

Journal Articles

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.

Francisco J. Hernandez-Ilizaliturri, MD, Arshad Iqbal, MS, Naheed Alam, MD, Seema Bhat, MD, Scott Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2006) 108 (11): 2523.

https://doi.org/10.1182/blood.V108.11.2523.2523

Published: 2006

Journal Articles

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas.

Francisco J. Hernandez-Ilizaliturri, MD, Seema Bhat, MD, Arshad Iqbal, MS, Scott Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2006) 108 (11): 2502.

https://doi.org/10.1182/blood.V108.11.2502.2502

Published: 2006

Journal Articles

Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin’s Lymphoma (NHL) Pre-Clinical Models.

Francisco J. Hernandez-Ilizaliturri, MD, Suresh Devineni, MD, Sarika Arora, MBBS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2005) 106 (11): 1473.

https://doi.org/10.1182/blood.V106.11.1473.1473

Published: 2005

Journal Articles

Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

Francisco J. Hernandez-Ilizaliturri, MD, Scott H. Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2005) 106 (11): 1474.

https://doi.org/10.1182/blood.V106.11.1474.1474

Published: 2005

Journal Articles

In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin’s Lymphoma Cells (NHL).

Myron S. Czuczman, MD, Sreeram Maddipatla, MD, Joy Knight, MS, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2005) 106 (11): 1475.

https://doi.org/10.1182/blood.V106.11.1475.1475

Published: 2005

NARROW

Lenalidomide Enhances the Biological Activity of Galiximab Against Non-Hogkin’s Lymphoma In Vitro and In Vivo .

GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens.

Methylseleninic Acid (MSA) Decreases DNA Synthesis, Induces Cell Death, and Sensitizes Both Rituximab Sensitive and Rituximab-Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Cisplatin and Gemcitabine.

Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF) Enhances Mapatumumab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) Against Non-Hodgkin’s Lymphoma (NHL) Cell Lines Independent of NADPH Oxidase-Derived Reactive Oxidant Intermediates (ROIs).

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.

Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas.

Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin’s Lymphoma (NHL) Pre-Clinical Models.

Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin’s Lymphoma Cells (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only